Prot #X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum

Project: Research project

Project Details

StatusFinished
Effective start/end date3/19/15 → 3/19/18

Funding

  • Therapeutics, Inc. (Prot #X052171 // Prot #X052171)
  • XOMA (US) LLC (Prot #X052171 // Prot #X052171)